SAB Biotherapeutics Balance Sheet Health
Financial Health criteria checks 5/6
SAB Biotherapeutics tiene unos fondos propios totales de $15.3M y una deuda total de $541.6K, lo que sitúa su ratio deuda/fondos propios en 3.6%. Sus activos y pasivos totales son $28.3M y $13.1M respectivamente.
Key information
1.8%
Debt to equity ratio
US$1.05m
Debt
| Interest coverage ratio | n/a |
| Cash | US$56.57m |
| Equity | US$57.30m |
| Total liabilities | US$26.64m |
| Total assets | US$83.94m |
Recent financial health updates
Recent updates
Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified
Apr 17
Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week
Jan 20Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues
Nov 19Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 18SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial
Sep 28What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates
Aug 12SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03
Aug 10Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term
Apr 06SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies
Dec 02Financial Position Analysis
Pasivos a corto plazo: SABSLos activos a corto plazo ($58.9M) de la empresa superan a sus pasivos a corto plazo ($10.8M).
Pasivo a largo plazo: SABSLos activos a corto plazo ($58.9M) superan a sus pasivos a largo plazo ($15.8M).
Debt to Equity History and Analysis
Nivel de deuda: SABS tiene más efectivo que su deuda total.
Reducción de la deuda: No se dispone de datos suficientes para determinar si el ratio deuda/fondos propios de SABS se ha reducido en los últimos 5 años.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Cash runway estable: SABS tiene suficiente margen de tesorería para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: SABS dispone de suficiente liquidez para 1.6 años si el flujo de caja libre sigue reduciéndose al ritmo histórico de 39% cada año.